Smary We report the safety and efficacy of autologous bone marrow transplantation (ABMT) in 30 patients with high-grade non-Hodgkin's lymphoma (NHL) in first complete remission (CR1) following remission induction chemotherapy. Two patients relapsed prior to ABMT. All patients were conditioned with high-dose melphalan. In addition, ten received fractionated total body irradiation, one hemi-body irradiation and four high-dose etoposide. Unmanipulated non-cryopreserved autologous marrow was reinfused within 56 h of harvesting. Engraftment occurred in all patients with a median of 11 days of neutropenia (<0.5 x 109 1'), a median requirement for platelet transfusion of 3 days and packed red cell transfusion of 2 units, with a median hospital stay of 18 days post transplant. There was no procedure-related mortality and only minor morbidity was observed. Two patients relapsed at 1 and 2 months post transplantation, and one patient died of carcinoma of the lung 33 months after transplantation. The remaining 25 patients remain alive, well and in CR1 with a median follow-up of 44 months. The event-free survival at 3 years for all patients considered for ABMT was 83%. We conclude that ABMT for high-grade NHL in CR1 with noncryopreserved marrow results in rapid haematological recovery without growth factor support. It is safe and is associated with high survival when used as consolidation of CR in high-risk patients.
The outcome of treatment for high-grade non-Hodgkin's lymphoma (NHL) has improved in recent years with the adoption of more intensive chemotherapeutic regimens. Many centres report complete response rates of 70-80% in highgrade NHL (Armitage et al., 1986; Skarin, 1986; Coiffier et al., 1989) . When patients relapse the prognosis is poor, although survival has improved with the development of more aggressive chemotherapeutic salvage regimens. Dose tolerance, limited by marrow toxicity, can be extended by the use of autologous bone marrow transplantation (ABMT). This approach has been used successfully in patients with relapsed high-grade NHL, although the procedural morbidity and mortality is substantial and relapse rates of around 50% are common (Gribben et al., 1989; Petersen et al., 1990) . We have previously reported the lack of toxicity associated with the use of ABMT in first remission in adult patients with high-grade lymphoproliferative disorders (Carey et al., 1991) . The relatively disappointing long-term results with conventional chemotherapy in high-risk, high-grade NHL encouraged us to investigate the use of early intensification using ABMT following remission induction in this group of patients. The aim was to assess whether early intensification with minimal toxicity would help to sustain complete remission and lead to prolonged disease-free survival.
Patients and methods
Thirty patients (21 males, nine females) with high-risk, highgrade NHL (Kiel classification) in CR1 were referred for consideration of ABMT between January 1984 and December 1991. Median age for all patients was 38 years (range Hayward et al. (1991) . This index, subsequently validated (Leonard et al., 1993) , delineates a good-risk group with an event-free survival of 54%, an intermediate-risk group with an event-free survival of 31% and a worst-risk group with 11% event-free survival (Table I) .
The application of the SNLG index to this patient cohort indicated that seven patients had an index <2.0 (good prognosis), six patients an index of 2.0-2.59 (intermediate prognosis) and 17 an index >2.6 (poor prognosis). No patient referred for consideration of ABMT declined the procedure, and all patients gave fully informed consent. Two patients relapsed prior to transplantation and were treated with salvage chemotherapy. The median time to transplant from diagnosis was 9 months (range 6-12) with remission induction chemotherapy taking approximately 5 months and local radiotherapy another month in those patients with bulk disease. In all patients bone marrow biopsy was performed (Taylor et al., 1993) , the last four patients in this study received HDM and HDE, as it was hoped that this regimen might improve efficacy without increasing toxicity. Both melphalan and etoposide have a short half-life, and it is possible to give sequential high doses of both drugs and still utilise non-cryopreserved marrow rescue.
Autotransplantation procedure At the time of marrow harvest, patients were anaesthetised and given 2,000-3,000 IU of sodium heparin intravenously.
Bone marrow was aspirated from the posterior iliac crests into acid citrate dextrose anticoagulant in standard blood transfusion collection packs, to give a median nucleated cell dose of 3.2 x 10' per kg recipient weight (range 1.91-4.8). The length of procedure including general anaesthetic was less than 60 min.
Harvested marrow was kept at 4-C for up to 56 h. Conditioning proceeded with melphalan 3 mg kg-I body weight by intravenous infusion immediately after drug reconstitution using a container protected from light. Patients receivimg etoposide were given a total dose of 1,600 mg m-2 as a continuous intravenous infusion over 20 h. TBI was given to ten patients to a total dose of 1,050cGy in three fractions each of 350 cGy. The three fractions were given over 24 h to allow reinfusion of the unmanipulated non-cryoprved marrow within 56 h of harvesting, using a standard blood transfusion giving set.
Supportive care
Patients were nursed in single rooms and received standard supportive care during haematological recovery. All patients were given acyclovir, oral nystatin and oral amphotericin prophylactically. Multiple donor platelet transfusions were given to maintain the platelet count about 20 x 10 1-' and red cell transfusions to maintain the haemoglobin above lOgdl-'. All cellular blood products for transfusion were irradiated and CMV antibody negative. Three patients (2, 10, 13) received recombinant granulocyte colony-stimulating factor (rG-CSF) as part of a large multinational trial of rG-CSF therapy following ABMT.
Reudts
Haematological reconstitution Neutrophil and platelet recovery occurred without delay in all patients. The rate of recovery did not vary with the differing conditioning therapies. Median number of days of neutropenia (<0.5 x l09 1-') was 11 (range 7-20) . Median number of days to a platelet count of > 50 x I0'-I was 22 (range 13-49), but patients required transfusion of platelet concentrates on a median of only three occasions (range 1-18), and required a median of 2 units (range 0-9) of packed red cells. The conditoning regimen used did not influence neutrophil or platelet recovery times.
Other toxicity
Mild oral mucositis was common (WHO grade <3). Alopecia (WHO grade 3) was universal. Nausea was minimal in patients reciving HDM and was controlled with metoclopramide. More recently, ondansetron 8 mg b.d. was used with good effect in patients receiving HDM and etoposide. The median number of days on which non-prophylactic antibiotics were given was 11 (range 0-23). There were no renal, hepatic or pulmonary complications, and no patient required intensive care. Patients stayed a median of 18 days (range 13-41) in hospital post transplant. There was no procedurerelated mortality.
Effect on disease Actuarial event-free survival from the time of transplant for all patients considered for ABMT (including the two patients who relapsed prior to ABMT who were 'taken off at '0' time) is 83% with a median follow-up of 44 months from the point of tranWlant (Figure 1 ). Only two very early relapses post ABMT, at 1 and 2 months, have occurred in the 28 patients transplanted in CR1. In addition, one patient, who had also had previous Hodgin's disease, died 3 years post transplant from squamous carcinoma of the lung without evidence of lymphoma recurrence.
In high-grade NHL patients with advanced disease, the potential value of high-dose chemotherapy followed by ABMT has been reported (PhilLps et al., 1984; Gribben et al., 1989; Petersen et al., 1990) . Many centres have used this form of therapy for patients in relapse or in second or third remission, and they have used very intensive conditioning regimens requiring marrow cryopreservation. Additionally, some centres have used marrow-purging techniques. A reluctance to undertake high-dose therapy with marrow rescue in first complete remission has been expressed (Gribben et al., 1987) because of procedure-related mortality rates of around 20% in the larger reported series performed in advanced disease, and because of the difficulty of proving efficacy in patients in first complete remission, in whom the prognosis is more favourable than in patients with advanced disea.
The effiacy, low procedural morbidity, absent mortality and encouraging results associated with unmanipulated non-opreserved ABMT in patients with acute lymphoblastic with high-grade NHL were perceived to be at high risk of kaemia (Proctor et al., 1988) prompted this phase II study relapse following conventional therapy using criteria similar NBMT in NHL patients in first CR (some of whom have to those identified by Coleman et al. (1986) . Although the ady been reported; Carey et al., 1991 form of preconditioning, neverthels the trend of improved event-free survival for such difficult patients remains encouraging. Other single-centre studies with similar patient populations to the present study have been performed utilisiDgmore ablative chemotherapy regimens and marrow purging in some studies (Philip et al., 1988; Colombat et al., 1990; Nademanee et al., 1992; Freedman et al., 1993) . All these studie have provided encouraging data and included substantial proportions of intermediate NHL according to the Working Formulation as in the present study. The Stanford study on 20 patients reports an 84% disease-free survival at 3 years when transplanted in first CR (Nademanee et al., 1992) . Philip et al. (1988) and a series from the Dana Faber Cancer Centre (Freedman et al., 1993) reported similar promising results. The only substantial trial of autologous transplant in first CR versus intensive chemotherapy is that performed by the French National Lymphoma Group, and preliminary data presented at the American Society of Haematokogy Meeting in December 1993 (Haioun et al., 1993) indicated that in a formal trial setting well-dlivered aggressive chemotherapy consolidation is equivalent to autotransplant intensification in first CR.
With a median follow-up of nearly 4 years following transplant, the event-free survival of 83% in this group of 'highrisk', high-grade NHL patients considered for ABMT in first complete remission suggests that this may be a useful consolidation therapy following rmission induction chemo/ radiotherapy. Recently a number of indices have been developed to deineate poor-prognosis groups in patients with NHL (Hayward et al., 1991 As this study commenced 9 years ago the lactate dehydrogenase, a universally accepted and powerful prognostic factor, was not ahlays measured at diagnosis (see Table II ).
Despite not always being able to add this additional risk factor, 22 of our patients were in the high and high-intediate risk groups with the remaining eight patients in the low-intermediate prognostic group according to the International Non-Hodgkin's Lymphoma Prognostic Factors Project (The International Non-Hodgkin's Lymphoma Prognostic Factors Project, 1993) . The 5 year relapsefree survival rates after achieving complet remission for these groups according to the project were 46%, 32% and 66% respectively.
We have shown that ABMT without cryopresevation is a safe procedure which ments further study in patients with Clv. Oncol., 7, 1621 -1629 
